Zynerba Pharmaceuticals Inc (ZYNE)


Stock Price Forecast

Oct. 11, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Zynerba Pharmaceuticals Inc chart...

About the Company

at zynerba pharmaceuticals (nasdaq: zyne), we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with significant unmet medical needs. our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy, osteoarthritis, fragile x syndrome, fibromyalgia and peripheral neuropathic pain through these therapeutics. our development pipeline includes patent-protected synthetic transdermal cannabinoid products, cbd gel – zyn002 and thc pro-drug patch – zyn001, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.

CEO

Armando Anido

Exchange

NASDAQ

Website

http://zynerba.com/

$5M

Total Revenue

26

Employees

$70M

Market Capitalization

-1.59

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ZYNE News

Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome

1mon ago, source: ADVFN

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the U ...

Belite Bio Stock (NASDAQ:BLTE), Quotes and News Summary

1mon ago, source: Benzinga.com

Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive ...

Zynerba Pharmaceuticals Initiates Phase 2 Trial of Zygel™ in Autism Spectrum Disorder

22d ago, source: ADVFN

About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.

Alnylam Pharmaceuticals

3d ago, source: Forbes

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

MRNS Marinus Pharmaceuticals, Inc.

13h ago, source: Seeking Alpha

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure ...

Real Estate Deals: Bayer Pharmaceuticals opens $250 million cell therapy facility

6h ago, source:

German pharmaceutical giant Bayer is embarking on a new beginning in the East Bay with its $250 million Cell Therapy Launch ...

Catalyst Pharmaceuticals

2d ago, source: Forbes

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton ...

Rhythm Pharmaceuticals Inc RYTM

4d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Merrimack Pharmaceuticals Inc MACK

4d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Regeneron Pharmaceuticals, Inc.

1y ago, source: CNN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes ...

ARDS Aridis Pharmaceuticals, Inc.

6d ago, source: Seeking Alpha

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript

29d ago, source: Yahoo Finance

Mirum Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.66 EPS, expectations were $-0.33. MIRM isn't one of the 30 most popular stocks among hedge funds at the end of the ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...